福元医药(601089.SH)：参与国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), has participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results, which will positively impact its market share and future performance [1]. Group 1: Procurement Participation - On February 9, 2026, the company participated in the national organized procurement for drugs with expired agreements [1]. - The procurement results are expected to be implemented by the end of March 2026, allowing provincial medical institutions to sign contracts with manufacturers based on the selected results [1]. Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1]. - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which will have a positive effect on its future operating performance [1].